Akụkọ Ikpe nke Mmeghachi Omume zuru oke Ogologo Oge na Ọrịa Kansa Hepatocellular na Mkpụrụ ndụ T GPC3 CAR (CT011)

CT011 bụ ọgwụ GPC3 CAR T-cell nke na-achọ ọgwụgwọ kansa hepatocellular (HCC). CT011 natara ikike IND site na NMPA na 2019 maka ọgwụgwọ nke ndị ọrịa nwere ọrịa kansa siri ike nke GPC3, nke bụ nnwale IND mbụ nke China maka ọgwụgwọ CAR T-cell megide ọrịa kansa siri ike.

Na Ọgọst 18, 2022, CARsgen Therapeutics kwupụtara na akụkọ ikpe, nke akpọrọ "Nzaghachi zuru oke ogologo oge nke ọrịa kansa hepatocellular dị elu na mkpụrụ ndụ T-cell nke Glypican-3 Specific Chimeric Antigen Receptor gbakwunyere Sorafenib, akụkọ ikpe", ebipụtala na Frontiers in Immunology.

Ikpe ahụ gosiri otu nwoke dị afọ iri isii nke onye ọrịa Eshia nwere ọrịa hepatitis B (HBV) nke metụtara HCC, onye a wara ahụ na Mee 2018. Na Ọgọst 2018, ọrịa kansa imeju na ọrịa kansa akpa ume malitere mgbe a wachara ya ahụ, e mesịakwa nye ya transarterial chemoembolization (TACE) iji gwọọ ọnya imeju na mwepụ imeju iji gwọọ metastases akpa ume. Ọnwa abụọ ka e mesịrị, ọ gara n'ihu ma debanye aha ya na nnwale ahụike. Mgbe e debanyere aha ya, onye ọrịa ahụ mere leukapheresis maka imepụta mkpụrụ ndụ T-cell CAR-GPC3. Ụbọchị asaa ka leukapheresis gasịrị, onye ọrịa ahụ malitere ịnara 400 mg nke sorafenib ugboro abụọ kwa ụbọchị. Onye ọrịa ahụ natara usoro ọgwụgwọ CAR-GPC3 T cells (CT011) ugboro anọ ma kewaa usoro ọgwụgwọ ọ bụla n'ime infusions abụọ. Tupu usoro ọgwụgwọ CT011 ọ bụla, e mere lymphodepletion. Ngụkọta nke 4×10⁹A gbanyere mkpụrụ ndụ T CAR-GPC3.

A nabatara ọgwụgwọ njikọta CT011 plus sorafenib nke ọma. Onye ọrịa a nwetara nzaghachi akụkụ (PR) site na ọnwa nke atọ wee nweta CR n'ime ọnwa nke iri na abụọ mgbe usoro mbụ nke infusion CT011 gasịrị. Ọrịa ahụ enweghị ọganihu ọ bụla ruo ihe karịrị ọnwa 36 ma nọgide na-enwe ọnọdụ CR ruo ihe karịrị ọnwa 24 mgbe infusion mbụ gasịrị.

Dịka anyị maara, nke a bụ ikpe mbụ akọpụtara na CR mgbe ejiri ọgwụgwọ mkpụrụ ndụ CAR T mee ihe na ndị na-egbochi tyrosine kinase. Nsonaazụ ahụike gosiri na ọgwụgwọ njikọta nke mkpụrụ ndụ GPC3 CAR T na Sorafenib nwere ike ịbụ ụzọ ọhụrụ dị mma maka ndị ọrịa GPC3+ nwere HCC dị elu.

Ugbu a, enwere ọtụtụ nnwale ụlọ ọgwụ CAR-T ndị ọzọ na China, ha na-achọkwa ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ ọhụrụ na teknụzụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.

Nọmba ekwentị: 4008803716

Email：myimmnet@163.com